Label Changes for:
Pristiq (desvenlafaxine succinate) Extended-Release tablets
Changes have been made to the WARNINGS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.|
Summary of Changes to Contraindications and Warnings
|WARNINGS AND PRECAUTIONS||(5.2) Serotonin Syndrome or Neuroleptic Malignant
Syndrome (NMS)-like Reactions